Janus kinase inhibition (Janus kinase inhibitors (JAKi)) therapy in refractory anti-synthetase syndrome: A retrospective cohort study
Authors' conclusion
JAKi were effective in most refractory ASS patients as evidenced by improved skin rash, myositis, and ILD.
Study context
- Population
- Refractory anti-synthetase syndrome patients treated with JAKi, October 2020 to June 2023; all had interstitial lung disease (ILD)all with ILD
- Participants
- 20 patients
- Exposure
- Before vs after JAKi treatment
- Outcome
- Efficacy (significant improvement in clinical manifestations) and safety of JAKi
Methodological detailsreal-world clinical settings, single-group before–after comparison
- Real-world clinical settings
- Single-group before–after comparison
Main finding
As reported in the abstract
Significant improvement in clinical manifestations
Patients with significant improvement in clinical manifestations
14
70 %
Observational data: associations, not effects.
Further findings
Arthritis
P = 0.002
Rash
P = 0.012
Shortness of breath
P = 0.039
Cough
P = 0.012
CK levels (5 patients abnormally elevated prior treatment)
P = 0.043
- Myalgia
- P = 0.016
- Muscular weakness
- P = 0.012
- Erythrocyte sedimentation rate (ESR)
- P = 0.001
- C-reactive protein (CRP)
- P = 0.023
- CT score in ASS-ILD
- P = 0.001
- GC dose
- P = 0.001
Myalgia
- Improvement was noted for myalgia (50 % vs. 11.1 %)
Muscular weakness
- Improvement was noted for muscular weakness (61.1 % vs. 11.1 %)
ESR
- Decrease in ESR
CRP
- Decrease in CRP
CT score in ASS-ILD
- CT score reduced (188.75 ± 69.67 vs. 156.35 ± 74.62)
GC dose
- GC dose significantly reduced (21.42 ± 13.26 mg vs. 11.32 ± 8.59 mg)
Original publication
Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study. Semin Arthritis Rheum. Published 3 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →